Hims & Hers Health, Inc. Class A HIMS

Hims & Hers Health has delivered a very strong multi year share price move, and that run now puts fresh attention on whether the current valuation can be supported by its sales base. With recent headlines around new products and regulatory scrutiny, the question is how much of that is already reflected in what investors are paying for each dollar of revenue. Over the past 3 years, Hims & Hers Health has returned about 3.7x for shareholders, which puts significant weight on whether its...

Hims & Hers Health (NYSE:HIMS) introduced an AI native weight loss care platform built around a closed loop clinical system. The new offering uses continuous learning, real time monitoring, and automation to support clinician decisions within the weight loss program. Management positions the platform as a way to scale weight management services while aiming to keep safety controls embedded in workflows. The AI native weight loss care launch matters, but investors also need to weigh other...

Hims & Hers Health (HIMS) has been in the spotlight after a class action lawsuit and related regulatory complaints over data privacy and billing practices, raising fresh questions for investors about risk, governance, and long term business quality. Despite the legal headlines, Hims & Hers Health has seen mixed momentum, with the share price up 5.11% over the last week but down 13.32% across three months. The 1-year total shareholder return has fallen 49.62% after a very large 3-year gain of...

The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 40.2%, hitting $29.23 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

At first glance, Hims & Hers Health, Inc. (NYSE:HIMS) delivered the kind of result that investors typically reward. Revenue grew 38%, full-year guidance was increased, and the company completed an acquisition that management says positions it as the world’s leading consumer health platform. That made the quarter look like another strong growth report, although the […]

Key TakeawaysGross margin at Hims & Hers has fallen for eight straight quarters, from 79% in September 2024 to 64% in the quarter ended June 2026, even as revenue grew 40% year over year in that same latest quarter. Reported EBITDA margin turned negative in the March 2026 quarter and stayed there in June, at negative 8.

Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D

Hims & Hers Health has been hit with an FTC complaint and multiple securities class action lawsuits alleging improper sharing of sensitive health data and misleading billing practices, events that have already drawn regulatory scrutiny and legal pressure by mid‑2026. The allegations cut to the core of Hims & Hers’ telehealth model, putting its privacy assurances and subscription-based business practices under a spotlight that could reshape how it operates. Against this backdrop of FTC action...

Gap Inc. (NYSE: GAP) today announced the appointment of Kirsten Green, Founder and Managing Partner of Forerunner, to the company's Board of Directors, effective immediately.